论文部分内容阅读
目的 探讨核素 (或药物 ) 抗AFP抗体、1 31 I或 (1 2 5I) 抗AFP(AFP .McAb或AFPAb) MMC“双弹头”、1 2 5I LUF标记物治疗原发性肝癌病人的治疗效果及毒副反应。方法 1 用改良氯胺T法将纯化AFP抗体标记核素1 31 I或1 2 5I获得标记物1 31 I(或1 2 5) 抗AFP抗体 ;用改良氨胺T法和过碘酸钠氧化法标记核素1 31 I或1 2 5I与MMC制备“双弹头” :1 31 I 抗AFP单抗 (AFP .McAb) MMC(称双弹头I)和1 31 I(或1 2 5I) 抗AFP多抗 (AFPAb) MMC(称双弹头Ⅱ ) ;催化置换反应制备1 2 5I 超液化碘油 (1 2 5I LUF) ;2 治疗后行肿瘤放射免疫定位显像 ;3 治疗 :1 94例进入临床试验 :1 31 I 抗AFP(n =72 ) ,1 2 5I 抗AFP(n =2 2 ) ,抗癌药 抗AFP(n =2 1 ) ,1 31 I或1 2 5I 抗AFP MMC(n =41 ) ,1 2 5I LUF(n =38)。结果 1 治疗后病人瘤 /肝 (T/L)比值 ,以1 2 5I LUF(3 46) >双弹头 (2 2 6) >单一弹头 (1 5～ 2 5) ,T/L以ia途径 >iv ;2 早期研究的病例晚期者居多 ,1 31 I 抗AFP、1 2 5I 抗AFP和双弹头Ⅰ、Ⅱ治后 1年存率分别为 33 3 % (2 2 / 66)、47 1 % (8/ 1 7)和 58 5 % (2 4 / 4 1 ) ,以抗癌药 抗AFP最低 (1 9 0 % ) ,而1 2 5I LUF则高达 81 6 % (31 / 38) ,其中 1 8例加外照射者为 1 0 0 % (1 8/ 1 8)
Objective To investigate the therapeutic effect of nuclide (or drug) anti-AFP antibody, 131 I or (125 I) anti-AFP (AFP.McAb or AFPAb) MMC “double warhead” and 125 I LUF marker on patients with primary liver cancer Effects and side effects. Method 1 The purified AFP antibody labeled nucleotides 1 31 I or 1 2 5I were obtained by using the modified chloramine T method to obtain the labeled antibody 1 31 I (or 125); the modified Amin T method and sodium periodate were used to oxidize Act labeled nucleotides 1 31 I or 1 2 5I and MMC prepared “double warheads”: 1 31 I anti-AFP monoclonal antibody (AFP. McAb) MMC (called warhead I) and 1 31 I (AFPAb) MMC (double warhead II); catalytic replacement reaction preparation of 125I LU lipiodol (125I LUF); 2 after treatment of tumor radioimmunoimaging; 3 treatment: 1 94 cases of clinical Assays: 131I anti-AFP (n = 72), 125I anti-AFP (n = 2 2), anticancer anti-AFP (n = 21), 131I or 125I anti-AFP MMC 41), 1 2 5 I LUF (n = 38). Results 1 The ratio of tumor / liver (T / L) after treatment with 1 2 5I LUF (34 6)> 2 warheads (2 2 6)> 1 warhead (1 5 ~ 2 5) iv; 2 The majority of cases studied in the early stage were mostly late-stage patients. The 1-year survival rates of 131 I anti-AFP, 125 I anti-AFP and bistatic I and II were 33.3% (2/66) and 47.1% 8/15) and 58.5% (2 4/4 1) respectively, the lowest anti-cancer drug anti-AFP (190%), while the 125 I LUF was 81 6% (31/38), of which 18 Cases of external irradiation were 100% (18/18)